Status:
UNKNOWN
Evaluation of ExacTrac® Imaging Device for Repositioning Quality of Patients Undergoing an External ENT Radiotherapy
Lead Sponsor:
Centre Leon Berard
Conditions:
Cancer
Radiotherapy Side Effect
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Monocentric, category 2 study according to Jardé Law (minimal risks and constraints) of three prospective cohorts: Tumors located at the oropharynx, the oral cavity and the larynx-hypopharynx. The ma...
Detailed Description
The radiotherapy treatment preparation requires performing a dosimetric scanner (CT) of the patient in the treatment position, with the compression. The repositioning of the ENT sphere can be complex,...
Eligibility Criteria
Inclusion
- Age ≥ 18 years old
- Patient requiring an ENT radiotherapy with intensity modulation (IMR) in the oropharynx, oral cavity, hypopharynx or larynx with bilateral irradiation of the lymph node areas
- Treatment planned on an accelerator equipped with a CBCT and the ExacTract® device
- Patient affiliated to a social security system
- Informed consent dated and signed
Exclusion
- Pregnant or breastfeeding woman
- Patient under totorship, curatorship or legal protection
Key Trial Info
Start Date :
January 13 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 13 2024
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT04670991
Start Date
January 13 2021
End Date
October 13 2024
Last Update
March 15 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Leon Berard
Lyon, France, 69008